#USA #Denver #EmVenio Clinical Research #PCM Trials #Patient Navigator

EmVenio Clinical Research: A New Era in Clinical Trials

EmVenio Clinical Research has officially emerged from the unifying of PCM Trials and its subsidiaries, EmVenio Research and Clinical Trial Service. This rebranding not only signifies a strategic move toward consolidating strengths but also a commitment to enhancing global access to clinical trials for patients.

As announced on August 25, 2025, the integration aligns these trusted companies under a single name—EmVenio Clinical Research. This transformation aims to provide sponsors and contract research organizations with a comprehensive range of services designed to meet the needs of participants more effectively.

The Vision Behind the Rebranding

Greg Austin, president of PCM Trials and now EmVenio Clinical Research, articulated the vision behind this significant shift, emphasizing that combining three innovative companies sets a new standard for accessibility and precision in community-based clinical research. The EmVenio name reflects a commitment to empower and reach patients in ways traditional models cannot.

Expanded Global Reach

This unified brand operates across over 80 countries, taking advantage of mobile teams and local research sites to approach participants in their own environments. By centering trials in community contexts, EmVenio aims to inclusively gather diverse research populations that may have previously been overlooked, particularly those representing minority groups.

Introducing Patient Navigator™

In line with enhancing accessibility, EmVenio is excited to announce the launch of Patient Navigator™, a tailored support service designed to mitigate logistical and financial barriers faced by potential trial participants. This offering is especially critical in areas like pediatrics and rare diseases, where patient participation can be daunting.

Patient Navigator™ provides a wide range of assistance, including coordinating travel arrangements and financial reimbursements, thereby addressing the hurdles that could otherwise impede participation in clinical trials. This service is designed to not only enhance patient retention rates but also to cultivate a deeper sense of engagement in the research process.

Legacy and Future Goals

Founded in 2008, PCM Trials made a name for itself as a pioneer in decentralized clinical trials, effectively bringing the trial experience directly into the homes of participants. The acquisition of Clinical Trials Service and EmVenio Research over the years has fortified this leading position and ushered in a new potential for global collaboration.

EmVenio Clinical Research’s track record speaks volumes: the organization boasts a recruitment success of over 75% minority patients and maintains a participant retention rate exceeding 92%. This solid foundation undergirds the future mission to ensure clinical research is more approachable and reflective of the diverse society it aims to serve.

A New Standard in Clinical Research

As EmVenio Clinical Research embarks on this new chapter, the organization remains committed to bridging the gap between scientific research and the communities it impacts. By focusing on empathy and close collaboration, EmVenio aims to deliver high-quality studies enriched by the real-world contexts of patients' lives.

In conclusion, the consolidation into EmVenio Clinical Research not only signifies a strategic alignment of capabilities but also marks a proactive step toward redefining patient engagement and access in clinical trials. As this unified entity moves forward, the transformative initiatives it introduces promise to set a new benchmark in the clinical research landscape.

For additional insights and information, visit emvenio.com.